HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $52

Benzinga · 3d ago
HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $54 to $52.